Pfizer (NYSE:PFE) recently presented groundbreaking findings in cancer research, particularly the first-in-human Phase 1 ...

When companies post strong earnings, the stock generally performs well, just like Pfizer Inc.'s ( NYSE:PFE ) stock ...

Pfizer faces several headwinds, including patent cliffs, regulatory risks, and a setback in obesity drug development. Click ...

Below is some historical data on the post-earnings performance of Pfizer stock compared to the stock performance of peers that reported their earnings just before Pfizer. For a fair comparison ...

Still, Pfizer stock has fallen 10% year to date and hasn’t provided the defensive hedge that many of its Zacks Large Cap Pharmaceutical peers have been able to provide, such as AbbVie ABBV ...